DOI: 10.5061/dryad.k0p2ngffp
title: Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study

description: Purpose: Infection by carbapenem-resistant Klebsiella
 pneumoniae (CRKP) has high mortality. There is
 no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim
 of this study was to compare the clinical outcomes and safety of the
 standard doses of polymyxin B-based regimens vs
 tigecycline-based regimens and to identify risk factors for
 mortality. Methods: This retrospective cohort study included
 patients with pneumonia caused by CRKP for three years. The primary
 outcomes were 7-day bacterial eradication rate and 14- and 28-day
 all-cause mortality. The secondary outcome was incidence of acute kidney
 injury. Results: Seventy-three patients were included in
 this study, 29 in the polymyxin B-based combination therapy group
 and 44 in tigecycline-based combination therapy
 group. There were no significant differences between the two
 groups in terms of the 7-day bacterial eradication rate
 (31.0% vs 20.5%, P=0.409), the 14-day
 all-cause mortality (37.9% vs
 22.7%, P=0.160), and the incidence of acute
 kidney injury (14.3% vs
 6.8%, P=0.526). The 28-day
 all-cause mortality in the polymyxin B-based
 therapy group was higher than in the
 tigecycline-based group (75.9% vs
 45.5%, P=0.010). Binary logistic regression analysis
 revealed that male and previous use of carbapenems were
 independent factors associated with 28-day all-cause
 mortality for patients treated with polymyxin B (P＜0.05).
 Conclusions: Polymyxin B-based combination therapy
 at the standard dose should be used with caution
 for patients with CRKP-induced pneumonia, especially for
 men who used carbapenems prior to CRKP detection.
description: # Data from: Clinical outcomes and safety of polymyxin B versus
 tigecycline combination therapy for pneumonia of carbapenem-resistant
 Klebsiella pneumoniae: A retrospective cohort study
 [https://doi.org/10.5061/dryad.k0p2ngffp](https://doi.org/10.5061/dryad.k0p2ngffp) ## Description of the data and file structure Background and purpose: Infection by carbapenem-resistant Klebsiella pneumoniae (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality. These datasets were collected from a tertiary hospital for three years. The following data were collected: 1. Demographic characteristics: age, sex 2. Patient's comorbidities: Charlson Comorbidity Index (CCI), 3. Invasive procedures during hospitalization, such as nasal feeding, foley catheter, central venous catheter, peripheral arterial catheter, CRRT, tracheotomy, gastroenterostomy, mechanical ventilatory, tracheoscopy, and parenteral nutrition. 4. The treatment of this hospitalization: overall duration of hospitalization in days, previously use antibiotics prior to CRKP infection, time to CRKP detected in days, co-infected with other carbapenem-resistant pathogens, phenotypic of carbapenemase, susceptibility of antibiotics, Acute Physiology and Chronic Health Evaluation II (APACHEII) score of first day on CRKP infection, laboratory variables of first day on CRKP infection,  details of polymyxin B use (loading dose, duration of treatment), co-administrated drugs, Cr at targeted regimen start, Cr until 48 h after the last dose. 5. The primary and secondary outcomes: bacterial clearance after 7-days, and all-cause mortality after 14 and 28 days. 6. We have added phenotypic of carbapenemase and the susceptibility results of minocycline, gentamicin, amicacin, aztreonam, and compound sulfamethoxazole in red font color. Missing values are replaced by average values.